Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Stock Information for Cue Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.